Persistence with cholinesterase inhibitor therapy for dementia: An observational administrative health database study

Drugs and Aging

Volumn 26, Issue 5, 2009, Pages 403-407

  Herrmann, Nathan ^a,b   Binder, Carin ^c   Dalziel, William ^d,e   Smyth, Steve ^c   Camacho, Fernando ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c Janssen Ortho Inc   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e Regional Geriatric Assessment Program of Ottawa   (Canada)

^f DAMOS Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

AGED; ARTICLE; CONTROLLED STUDY; DEMENTIA; DOSAGE SCHEDULE COMPARISON; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DATABASES, FACTUAL; DELAYED-ACTION PREPARATIONS; DEMENTIA; FOLLOW-UP STUDIES; GALANTAMINE; HUMANS; INDANS; MEDICATION ADHERENCE; PHENYLCARBAMATES; PIPERIDINES;

EID: 68149131606     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/00002512-200926050-00004     Document Type: Article

References (13)

1. Canadian Study of Health and Aging Working Group. Canadian study of health and aging: study methods and prevalence of dementia. Can Med Assoc J 1994; 150: 899-913
2. Thompson S, Lanctot KL, Herrmann N. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease. Expert Opin Drug Saf 2004; 3: 425-40
3. Hogan DB, Bailey P, Carswell A, et al. Management of mild to moderate Alzheimer's disease and dementia. Alzheimers Dement 2007; 3: 355-84
4. Herrmann N, Gauthier S, Lysy P. Clinical practice guidelines for severe Alzheimer's disease. Alzheimers Dement 2007; 3: 385-97
5. Mauskopf JA, Paramore C, Lee WC, et al. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Manag Care Pharm 2005; 11: 231-51
6. Suh DC, Thomas SK, Valiyeva E, et al. Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease. Drugs Aging 2005; 22: 695-707
7. Dybicz SB, Keohane DJ, Erwin WG, et al. Patterns of cholinesterase- inhibitor use in the nursing home setting: a retrospective analysis. Am J Geriatr Pharmacother 2006; 4: 154-60
8. Sicras-Mainar A, Vergara J, Leon-Colombo T, et al. Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine. Rev Neurol 2006; 43: 449-53
9. Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007; 55: 1517-23
10. Seltzer B. Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified? Drugs Aging 2007; 24: 881-90
11. Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci 2005; 26: 104-11
12. AD 2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD 2000): randomised double-blind trial. Lancet 2004; 363: 2105-15
13. Fillit H, Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother 2005; 3: 39-49